Literature DB >> 32714543

A retrospective review of 145 patients with angiosarcoma: Radiation therapy, extent of resection and chemotherapy are important predictors of survival.

Alannah Smrke1, Jeremy Hamm2, Anand Karvat3, Christine Simmons1, Amirrtha Srikanthan4.   

Abstract

Angiosarcoma is a subset of soft-tissue sarcomas with poor 5-year survival rate. Given its rarity, limited large cohort data is available for this disease. Therefore, the present study evaluated data from patients with angiosarcoma treated at a provincial Institution (BC Cancer) to determine potential modifiable predictors of survival. A retrospective review of patients across British Columbia (Canada) was conducted at the Sarcoma Outcome Unit of BC Cancer from January 1, 1969 to September 19, 2017. Cox proportional hazard models were used to calculate hazard ratios (HR) for the overall survival (OS) and progression free survival (PFS) of patients. A total of 145 patients with angiosarcoma were identified, of which 68 were metastatic/unresectable at presentation. Of the 145 patients included, 38 received chemotherapy, with 15 receiving taxane. A single patient received chemotherapy in a neoadjuvant setting. Of the resectable patients, 71 had first line surgery and 38 had curative-intent radiation during their treatment. Of the study cohort, 38 patients received prior radiation for an unrelated cancer and 4 patients had pre-existing chronic lymphedema. Resectable disease (HR, 0.22; P<0.01), first treatment with either surgery (HR, 0.08; P<0.01), radiation (HR, 0.19; P<0.01) or chemotherapy (HR, 0.22; P<0.01) were predictors of improved OS. First line surgery resulted in improved OS (HR, 0.36; P<0.01) and PFS (HR, 0.48; P<0.01). In addition, OS was positively impacted by the extent of surgery [complete (R0) vs. microscopic residual tumor (R1); HR, 0.26; P<0.01; R0 vs. macroscopic residual tumor (R2); HR, 0.08; P<0.01) resection. Extent of surgery and any radiation treatment were determined to be important predictors of OS. The results also revealed that patient outcome was improved following any treatment compared with supportive care alone. In conclusion, multidisciplinary care is critical for the treatment of patients diagnosed with angiosarcoma.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  angiosarcoma; anthracyclines; radiation associated sarcoma; soft tissue sarcoma; taxanes

Year:  2020        PMID: 32714543      PMCID: PMC7366222          DOI: 10.3892/mco.2020.2055

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  19 in total

1.  Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.

Authors:  Antoine Italiano; Angela Cioffi; Nicolas Penel; Matteo Giaj Levra; Corinne Delcambre; Elsa Kalbacher; Christine Chevreau; François Bertucci; Nicolas Isambert; Jean-Yves Blay; Binh Bui; Cristina Antonescu; David R D'Adamo; Robert G Maki; Mary Louise Keohan
Journal:  Cancer       Date:  2011-11-01       Impact factor: 6.860

2.  Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Authors:  A Le Cesne; M Ouali; M G Leahy; A Santoro; H J Hoekstra; P Hohenberger; F Van Coevorden; P Rutkowski; R Van Hoesel; J Verweij; S Bonvalot; W P Steward; A Gronchi; P C W Hogendoorn; S Litiere; S Marreaud; J Y Blay; W T A Van Der Graaf
Journal:  Ann Oncol       Date:  2014-10-06       Impact factor: 32.976

3.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

4.  Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.

Authors:  Keith M Skubitz; Philip A Haddad
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

5.  Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience.

Authors:  Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

6.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.

Authors:  Sylvie Bonvalot; Michel Rivoire; Marine Castaing; Eberhard Stoeckle; Axel Le Cesne; Jean Yves Blay; Agnès Laplanche
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

Authors:  M Schlemmer; P Reichardt; J Verweij; J T Hartmann; I Judson; A Thyss; P C W Hogendoorn; S Marreaud; M Van Glabbeke; J Y Blay
Journal:  Eur J Cancer       Date:  2008-09-02       Impact factor: 9.162

8.  Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.

Authors:  Timothy M Pawlik; Augusto F Paulino; Cornelius J McGinn; Laurence H Baker; Deborah S Cohen; Jeffery S Morris; Riley Rees; Vernon K Sondak
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 9.  Angiosarcoma. A report of 67 patients and a review of the literature.

Authors:  R J Mark; J C Poen; L M Tran; Y S Fu; G F Juillard
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

Review 10.  Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

Authors:  Mark Linch; Aisha B Miah; Khin Thway; Ian R Judson; Charlotte Benson
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

View more
  3 in total

1.  Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.

Authors:  Jong Hyuk Kim; Kate Megquier; Rachael Thomas; Aaron L Sarver; Jung Min Song; Yoon Tae Kim; Nuojin Cheng; Ashley J Schulte; Michael A Linden; Paari Murugan; LeAnn Oseth; Colleen L Forster; Ingegerd Elvers; Ross Swofford; Jason Turner-Maier; Elinor K Karlsson; Matthew Breen; Kerstin Lindblad-Toh; Jaime F Modiano
Journal:  Mol Cancer Res       Date:  2021-03-01       Impact factor: 6.333

2.  Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology.

Authors:  Inna Schott; Sven-Thorsten Liffers; Farhad Farzaliyev; Johanna Falkenhorst; Hans-Ulrich Steinau; Jürgen-Walter Treckmann; Lars Erik Podleska; Christoph Pöttgen; Hans-Ulrich Schildhaus; Marit Ahrens; Uta Dirksen; Fatma-Zehra Murat; Jens T Siveke; Sebastian Bauer; Rainer Hamacher
Journal:  Sarcoma       Date:  2021-09-10

3.  Pretreatment tumor sampling and prognostic factors in patients with soft-tissue sarcoma of the head and neck.

Authors:  Johan H Roos; Antti A Mäkitie; Jussi Tarkkanen; Taru T Ilmarinen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-12       Impact factor: 3.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.